BVI® is refocusing the future of vision. As one of the fastest-growing, diversified surgical ophthalmic businesses in the world, our purpose-built portfolio includes single-use instruments, equipment, premium intraocular lenses and vitreoretinal surgical products, and spans more than 90 countries.
Buyers Edge Platform
We’re transforming the foodservice supply chain with data and technology. It’s our mission to usher our partners into the digital age — where operators, manufacturers, and distributors have instant access to real-time information about their products, prices, and profitability. We support our manufacturer partners in gaining new business and accessing unprecedented Insights. We allow Foodservice operators to leverage our data and technology to reduce costs, elevate quality, alleviate supply chain issues, and gain insights into the strength of their purchasing functions. Our distributors partners work with us to gain unprecedented visibility to drive new business, penetrate additional market share, and reward and retain key clients with customized contracts that align to their marketing goals. The most powerful leaders and innovators in the foodservice industry partner with Buyers Edge Platform to deliver more value and profitability. We’re a data obsessed company, with thousands of ways to reduce costs for any segment.
BrightSpec
BrightSpec is an innovative life science tools company with a range of instruments that tap the power of molecular rotational resonance (MRR) spectroscopy. MRR enables the rapid, unambiguous molecular ID and quantitative analysis of mixtures, without separation, no chemometrics, and with no reference sample required.
BostonGene
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and AI. Built and validated through an extensive real-world clinical testing network, BostonGene’s foundation model for tumor and immune biology integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners design and de-risk trials, identify novel targets, and optimize therapeutic response prediction while improving patient care through clinically integrated innovation.
Boston Dynamics
Boston Dynamics’ mission is to imagine and create exceptional robots that enrich people’s lives. We see this work as the next step in the evolution of machines that reduce the danger, repetition, and physically difficult aspects of work. | Boston Dynamics’ mission is to imagine and create exceptional robots that enrich people’s lives. Building machines that can approximate the mobility, dexterity and agility of people and animals is a grand challenge. Curiosity and respect for the natural world are at the heart of our work on robots. We see products derived from this work as the next step in the human history of building machines to reduce the danger, repetition and physically difficult aspects of work. | Stretch Robot
Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab/RenLite®/RenNano®/RenTCR-mimic) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg).
BerryDunn
BerryDunn’s renewable energy team offers tax advisory, financial, and accounting services for cleantech companies involved in solar, wind, biomass, waste-to-energy, and energy-efficiency projects. We provide: Expert partnership/corporate structuring for optimal tax benefit Investment Tax Credit (ITC) study to determine qualified project costs Ongoing advisory services for federal, state and local tax incentives Specialized strategic financial planning and management to optimize cash flow and budgeting We can also serve as your primary accounting firm or augment your existing financial staff with our renewable energy tax and financial management expertise. Our personal approach, practical advice, and reasonable fee structures allow companies in every stage of the business lifecycle, from start-up to IPO, to take advantage of our expert knowledge and experience in renewable energy finances.
Ardelyx
Ardelyx is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. | With a vision of creating a healthier tomorrow, we are steadfast in our commitment to deliver first-in-class medicines to patients with unmet medical needs. We believe in working closely with patients and their caregivers, listening to their needs and insights, and setting new standards in product innovation, patient care, and community engagement.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. | We are delivering meaningful advances for patients with serious diseases who previously had few, or no, approved treatment options. Our medicines are making a difference for patients with: -Geographic atrophy (GA) – a leading cause of blindness -C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) – two severe, rare kidney diseases -Paroxysmal nocturnal hemoglobinuria (PNH) – a rare, life-threatening blood disorder. And we believe we have only begun to unlock the full potential of targeting C3 for patients. With perseverance and passion, we have advanced two C3-targeting medicines from discovery through development and commercialization. Today, we are leveraging our complement expertise to develop new treatments for patients living with serious diseases.